Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and lymphovascular invasion

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence , Retrospective Study.

NCT07275203

Breast Carcinoma

NOT_YET_RECRUITING

Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma

NCT06357338

Invasive Breast Cancer

ENROLLING_BY_INVITATION

Clinicopathological Parameters of HER2 Low Breast Cancers

NCT06433804

HER2 Low Breast Cancers

COMPLETED

EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

NCT05703815

Invasive Breast Cancer

UNKNOWN

Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer

NCT04683770

Breast Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinical data, pathological data, expression status of ER, PR and HER2/neu of both initial tumor and recurrent tumor and received treatment for BC patients diagnosed between January 2021 and December 2024 will be extracted from archive of multidisciplinary team (MDT) for management of BC at Sohag Oncology Center. In addition; hematoxylin and eosin stained slides and immune-stained slides for ER, PR and HER2/neu for selected patient's will be retrieved from archives of Pathology unit at Sohag Oncology Center and reviewed to confirm pathological features, ER expression, PR expression and HER2 status of both initial and recurrent tumor tissues.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

archived histological slides and immune-stained slides of 100 patient with breast cancer

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with excised breast cancer then experienced recurrence at same site. Patients with evaluated ER, PR and HER2/neu for both initial and recurrent tumors.